BRPI0605893A - composição farmacêutica, cápsula única, forma unitária de dosagem oral única, processos de produção de uma composição farmacêutica, dos ingredientes ativos cristalinos e recristalizado do ácido suberoilanilida hidroxámico, e de obtenção do ácido suberoilanilida hidroxámico cristalino, e, composição cristalina - Google Patents

composição farmacêutica, cápsula única, forma unitária de dosagem oral única, processos de produção de uma composição farmacêutica, dos ingredientes ativos cristalinos e recristalizado do ácido suberoilanilida hidroxámico, e de obtenção do ácido suberoilanilida hidroxámico cristalino, e, composição cristalina

Info

Publication number
BRPI0605893A
BRPI0605893A BRPI0605893-0A BRPI0605893A BRPI0605893A BR PI0605893 A BRPI0605893 A BR PI0605893A BR PI0605893 A BRPI0605893 A BR PI0605893A BR PI0605893 A BRPI0605893 A BR PI0605893A
Authority
BR
Brazil
Prior art keywords
crystalline
pharmaceutical composition
hydroxamic
acid
composition
Prior art date
Application number
BRPI0605893-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Jeannie Chow Wong
Aaron S Cote
Erik A Dienemann
Kimberly Gallagher
Craig Ikeda
Justin Moser
Pavol Rajniak
Robert A Reed
Cindy Starbuck
Hsien-Hsin Tung
Qingxi Wang
Benjamin Max Cohen
Vincent R Capodanno
Brian Sell
Thomas A Miller
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37452585&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0605893(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of BRPI0605893A publication Critical patent/BRPI0605893A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BRPI0605893-0A 2005-05-20 2006-05-16 composição farmacêutica, cápsula única, forma unitária de dosagem oral única, processos de produção de uma composição farmacêutica, dos ingredientes ativos cristalinos e recristalizado do ácido suberoilanilida hidroxámico, e de obtenção do ácido suberoilanilida hidroxámico cristalino, e, composição cristalina BRPI0605893A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68287505P 2005-05-20 2005-05-20
US69312805P 2005-06-23 2005-06-23
PCT/US2006/018737 WO2006127319A2 (en) 2005-05-20 2006-05-16 Formulations of suberoylanilide hydroxamic acid and methods for producing same

Publications (1)

Publication Number Publication Date
BRPI0605893A true BRPI0605893A (pt) 2007-12-18

Family

ID=37452585

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0605893-0A BRPI0605893A (pt) 2005-05-20 2006-05-16 composição farmacêutica, cápsula única, forma unitária de dosagem oral única, processos de produção de uma composição farmacêutica, dos ingredientes ativos cristalinos e recristalizado do ácido suberoilanilida hidroxámico, e de obtenção do ácido suberoilanilida hidroxámico cristalino, e, composição cristalina

Country Status (20)

Country Link
US (4) US8093295B2 (enExample)
EP (2) EP1853245A2 (enExample)
JP (2) JP5264174B2 (enExample)
KR (2) KR100993135B1 (enExample)
AR (1) AR055953A1 (enExample)
AU (3) AU2006249440C1 (enExample)
BR (1) BRPI0605893A (enExample)
CA (1) CA2580367C (enExample)
CR (1) CR8912A (enExample)
DO (1) DOP2006000113A (enExample)
EC (1) ECSP077263A (enExample)
IL (1) IL181070A0 (enExample)
MA (1) MA28804B1 (enExample)
MX (1) MX2007002047A (enExample)
MY (1) MY144613A (enExample)
NI (1) NI200700031A (enExample)
NZ (2) NZ594669A (enExample)
PE (1) PE20061390A1 (enExample)
TW (2) TWI365068B (enExample)
WO (2) WO2006127319A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI365068B (en) * 2005-05-20 2012-06-01 Merck Sharp & Dohme Formulations of suberoylanilide hydroxamic acid and methods for producing same
CA2740559C (en) 2008-10-15 2016-02-16 Generics [Uk] Limited Improved process
WO2010061220A2 (en) * 2008-11-26 2010-06-03 Generics [Uk] Limited Novel processes and pure polymorphs
CA2744448A1 (en) * 2008-11-26 2010-06-03 Vinayak Gore Polymorphs
US20110313044A1 (en) * 2010-06-18 2011-12-22 Urquima S.A. Polymorphs of Suberoylanilide Hydroxamic Acid
EP3484470A4 (en) 2016-07-13 2020-02-26 Technion Research & Development Foundation Limited INHIBITORS OF HISTONE DEACETYLASE 4 CYTOPLASMIC COMPLEX FOR THE TREATMENT OR PREVENTION OF VASCULAR OR VALVULAR CALCIFICATION
CN107362148B (zh) * 2017-07-27 2020-04-21 东曜药业有限公司 一种治疗肿瘤的药物组合物及其制备方法和应用
EP4007585A4 (en) 2019-08-02 2023-11-08 OneHealthCompany, Inc. TREATMENT OF CANINE CANCERS

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
JPS61176523A (ja) * 1985-01-30 1986-08-08 Teruhiko Beppu 制癌剤
US5055608A (en) * 1988-11-14 1991-10-08 Sloan-Kettering Institute For Cancer Research Novel potent inducers of thermal differentiation and method of use thereof
US5608108A (en) * 1988-11-14 1997-03-04 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and method of use thereof
US5175191A (en) * 1988-11-14 1992-12-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5369108A (en) * 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
USRE38506E1 (en) * 1991-10-04 2004-04-20 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5700811A (en) * 1991-10-04 1997-12-23 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and method of use thereof
US5635532A (en) * 1991-10-21 1997-06-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia
JP3170069B2 (ja) * 1992-10-06 2001-05-28 日水製薬株式会社 徐放性顆粒剤
US6043389A (en) * 1997-03-11 2000-03-28 Mor Research Applications, Ltd. Hydroxy and ether-containing oxyalkylene esters and uses thereof
US6030961A (en) 1997-03-11 2000-02-29 Bar-Ilan Research & Development Co., Ltd. Oxyalkylene phosphate compounds and uses thereof
US6124495A (en) 1997-03-11 2000-09-26 Beacon Laboratories, Inc. Unsaturated oxyalkylene esters and uses thereof
US6231880B1 (en) * 1997-05-30 2001-05-15 Susan P. Perrine Compositions and administration of compositions for the treatment of blood disorders
AUPO721997A0 (en) 1997-06-06 1997-07-03 Queensland Institute Of Medical Research, The Anticancer compounds
US6262116B1 (en) * 1998-01-23 2001-07-17 Sloan-Kettering Institute For Cancer Research Transcription therapy for cancers
CZ20011342A3 (cs) 1998-10-13 2001-09-12 Fujisawa Pharmaceutical Co., Ltd. Cyklické tetrapeptidy
CA2366408A1 (en) 1999-05-03 2000-11-30 Methylgene, Inc. Inhibition of histone deacetylase
JP2001081031A (ja) 1999-08-30 2001-03-27 Schering Ag 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤
AU6932700A (en) * 1999-09-08 2001-04-10 Sloan-Kettering Institute For Cancer Research Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof
KR20020070285A (ko) 1999-11-23 2002-09-05 메틸진, 인크. 히스톤 디아세틸라제의 억제제
ATE489360T1 (de) 2000-03-24 2010-12-15 Methylgene Inc Inhibitoren der histon-deacetylase
WO2002015921A2 (en) 2000-08-18 2002-02-28 The Governement Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methods of treating cutaneous and peripheral t-cell lymphoma by a histone deacetylase inhibitor
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
JP4975941B2 (ja) 2000-09-29 2012-07-11 トポターゲット ユーケー リミテッド （ｅ）−ｎ−ヒドロキシ−３−（３−スルファモイル−フェニル）アクリルアミド化合物及びその治療用途
WO2002055017A2 (en) 2000-11-21 2002-07-18 Wake Forest University Method of treating autoimmune diseases
AR035659A1 (es) 2000-12-07 2004-06-23 Hoffmann La Roche Hidroxiamidas de acido (1-oxo-1,2,3,4-tetrahidro-naftalen-2-il)-alcanoico, proceso para la manufactura de estos compuestos, composiciones farmaceuticas que contienen dichos compuestos y los usos de los mismos
US6495719B2 (en) * 2001-03-27 2002-12-17 Circagen Pharmaceutical Histone deacetylase inhibitors
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
US7199227B2 (en) * 2001-06-14 2007-04-03 Bristol-Myers Squibb Company Polynucleotides encoding human histone deacetylase HDAC9c
JP4638148B2 (ja) * 2001-10-16 2011-02-23 スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ 神経変性疾患および脳の癌の処置
US20040132643A1 (en) * 2002-01-09 2004-07-08 Fojo Antonio Tito Histone deacelylase inhibitors in diagnosis and treatment of thyroid neoplasms
US20030235588A1 (en) * 2002-02-15 2003-12-25 Richon Victoria M. Method of treating TRX mediated diseases
US20040132825A1 (en) * 2002-03-04 2004-07-08 Bacopoulos Nicholas G. Methods of treating cancer with HDAC inhibitors
CN1720034A (zh) * 2002-03-04 2006-01-11 艾顿药物公司 诱导末期分化的方法
US20060276547A1 (en) * 2002-03-04 2006-12-07 Bacopoulos Nicholas G Methods of treating cancer with HDAC inhibitors
US7148257B2 (en) * 2002-03-04 2006-12-12 Merck Hdac Research, Llc Methods of treating mesothelioma with suberoylanilide hydroxamic acid
US20070060614A1 (en) * 2002-03-04 2007-03-15 Bacopoulos Nicholas G Methods of treating cancer with hdac inhibitors
US7456219B2 (en) 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
MXPA04010199A (es) * 2002-04-15 2005-07-05 Sloan Kettering Inst Cancer Terapia en combinacion para el tratamiento de cancer.
DE10218106A1 (de) * 2002-04-23 2003-11-20 Jenapharm Gmbh Verfahren zum Herstellen von Kristallen von Arzneimittelwirkstoffen, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
WO2004046104A2 (en) * 2002-11-20 2004-06-03 Errant Gene Therapeutics, Llc Treatment of lung cells with histone deacetylase inhibitors
EP1613592A4 (en) * 2003-04-01 2008-03-12 Sloan Kettering Inst Cancer HYDROXAMIC ACID COMPOUNDS AND METHODS OF USE THEREOF
KR100924737B1 (ko) * 2003-08-26 2009-11-04 슬로안-케테링인스티튜트퍼캔서리서치 Ｈｄａｃ 억제제를 이용한 암의 치료 방법
TWI365068B (en) * 2005-05-20 2012-06-01 Merck Sharp & Dohme Formulations of suberoylanilide hydroxamic acid and methods for producing same
CA2617623A1 (en) 2005-08-18 2007-02-22 Victoria M. Richon Combination methods of saha and targretin for treating cancer
JP2009514879A (ja) 2005-11-04 2009-04-09 メルク エンド カムパニー インコーポレーテッド Ｓａｈａ、カルボプラチン及びパクリタキセルを用いて癌を治療する方法及びその他の併用療法
CN101300015A (zh) * 2005-11-04 2008-11-05 默克公司 使用n-辛二酰苯胺异羟肟酸和厄洛替尼治疗癌症的方法
EP1947936A4 (en) * 2005-11-04 2010-02-10 Merck & Co Inc METHOD FOR THE USE OF SAHA AND BORTEZOMIB FOR THE TREATMENT OF CANCER

Also Published As

Publication number Publication date
US20080132575A1 (en) 2008-06-05
KR100993135B1 (ko) 2010-11-10
JP5308486B2 (ja) 2013-10-09
NZ594669A (en) 2013-02-22
DOP2006000113A (es) 2006-10-31
TWI365068B (en) 2012-06-01
US8288440B2 (en) 2012-10-16
US20100112046A1 (en) 2010-05-06
AU2009201650A1 (en) 2009-05-21
CA2580367A1 (en) 2006-11-30
AU2006249440C1 (en) 2009-08-13
AU2006249440A1 (en) 2006-11-30
MX2007002047A (es) 2007-04-12
AU2009201652A1 (en) 2009-05-21
KR20080113135A (ko) 2008-12-26
PE20061390A1 (es) 2007-01-15
TW201034660A (en) 2010-10-01
CR8912A (es) 2008-02-21
US8450372B2 (en) 2013-05-28
ECSP077263A (enExample) 2007-04-26
KR20070062505A (ko) 2007-06-15
JP2008519081A (ja) 2008-06-05
CA2580367C (en) 2012-08-21
AU2006249440B2 (en) 2009-03-12
IL181070A0 (en) 2007-07-04
NZ553204A (en) 2011-09-30
NI200700031A (es) 2008-03-03
KR100884500B1 (ko) 2009-02-20
AU2009201652B2 (en) 2011-10-06
WO2006127319A2 (en) 2006-11-30
JP5264174B2 (ja) 2013-08-14
US8093295B2 (en) 2012-01-10
US20100119596A1 (en) 2010-05-13
TW200727892A (en) 2007-08-01
WO2006127321A2 (en) 2006-11-30
MY144613A (en) 2011-10-04
TWI415603B (zh) 2013-11-21
EP1853245A2 (en) 2007-11-14
US20100113829A1 (en) 2010-05-06
WO2006127319A3 (en) 2007-03-29
JP2011251985A (ja) 2011-12-15
AU2009201650B2 (en) 2011-09-15
AR055953A1 (es) 2007-09-12
EP2292221A3 (en) 2011-08-10
EP2292221A2 (en) 2011-03-09
MA28804B1 (fr) 2007-08-01
AU2010201359A1 (en) 2010-04-29
WO2006127321A3 (en) 2007-03-22

Similar Documents

Publication Publication Date Title
ES2372421T3 (es) Uso de flibanserina para el tratamiento de trastornos del deseo sexual premenopáusicos.
HRP20171793T1 (hr) Farmaceutske formulacije koje sadrže kristalne oblike (r)-7-kloro-n-(kinuklidin-3-il)benzo(b)tiofen-2-karboksamid hidroklorid monohidrata
ECSP066914A (es) FORMA CRISTALINA dd DEL CLORHIDRATO DE LA IVABRADINA, SU PROCEDIMIENTO DE PREPARACIÓN Y LAS COMPOSICIONES FARMACÉUTICAS QUE LA CONTIENEN
MX2011012122A (es) Derivados de tiofeno.
MX2010011381A (es) Composiciones que comprenden farmacos levemente basicos y formas de dosificacion de liberacion controlada.
UY32599A (es) Formulación oral sólida de abt-263
NZ631100A (en) Soft chewable pharmaceutical products
EA201590449A1 (ru) Перорально вводимая лекарственная композиция
BR112012019374A2 (pt) composição farmacêutica, pellet de liberação prolongada, composição farmacêutica oral, método para tratamento de uma doença neurodegenerativa ou um dano ao sistema nervoso em um indivíduo necessitado do mesmo e método para preparação de uma formulação de liberação prolongada de um agente ativo
BRPI0517662A (pt) partìculas de ramipril estabilizadas revestidas, processo para o revestimento de ramipril, composição farmacêutica oral sólida, métodos para evitar e tratar distúrbios cardiovasculares, e, processo para fabricar uma composição farmacêutica
GEP20084468B (en) Gamma-d crystalline form of ivabradin hydrochloride, process for its preparation and pharmaceutical compositions containing it
UA104988C2 (uk) Похідні піроніндолу та спосіб їх отримання
BRPI0807285A2 (pt) "composição, método para preparar composição farmacêutica, forma unitária de dosagem, método para admnistrar um agente biologicamente ativo a um animal necessitando o agente, método para aumentar a biodisponibilidade de um agente biologicamente ativo, método para preparar uma composição e composto"
BR0314299A (pt) Derivados de pirrolidona como inibidores de mao-b
MA35455B1 (fr) (wo2013045407) dérivés d'estra-1,3,5(10),16-tétraène-3-carboxamide, procédé pour leur fabrication, préparations pharmaceutiques contenant ces substances ainsi que leur utilisation dans la fabrication de médicaments
AR095159A2 (es) Una composición farmacéutica en forma de cápsula para administración oral
BR112014014795A2 (pt) sistema de pélete de multiunidade de liberação imediata
JP2018521007A5 (enExample)
BRPI0605893A (pt) composição farmacêutica, cápsula única, forma unitária de dosagem oral única, processos de produção de uma composição farmacêutica, dos ingredientes ativos cristalinos e recristalizado do ácido suberoilanilida hidroxámico, e de obtenção do ácido suberoilanilida hidroxámico cristalino, e, composição cristalina
ECSP099602A (es) Sales de adición de ácido, hidratos y polimorfos de la etil-amida del ácido 5-(2,4-dihidroxi-5-isopropil-fenil)-4-(4-morfolin-4-il-metil-fenil)-isoxazol-3-carboxílico, y formulaciones que comprenden estas formas
JP2018039810A5 (enExample)
EP2746254A3 (en) Oxadiazole derivative active on sphingosine-1-phosphate (s1p)
BRPI0410623A (pt) composto, processo para preparação de um composto, composição farmacêutica, e, utilização de um composto
BRPI0602338A (pt) compostos orgánicos
BRPI0518789A2 (pt) formulaÇço farmacÊutica, processo para preparar uma formulaÇço farmacÊutica, produto, e, cÁpsula ou tablete

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: MERCK SHARP AND DOHME CORP. (US)

Free format text: ALTERADO DE: MERCK AND CO., INC.

B25A Requested transfer of rights approved

Owner name: SCHERING CORPORATION, (US)

B25D Requested change of name of applicant approved

Owner name: MERCK SHARP AND DOHME CORP. (US)

B25G Requested change of headquarter approved

Owner name: MERCK SHARP AND DOHME CORP. (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]